Physician profile
Sunil Abraham
NPI 1801080890
$4,310.55
in general payments reported to CMS, 2019-2025
23 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.45 · 2020: $20.53 · 2021: $121 · 2022: $694 · 2023: $861 · 2024: $1,003 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,753.90 | 2021-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $598.76 | 2020-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $229.38 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $226.81 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $223.03 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $195.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $180.62 | 2021-2025 | Saphnelo |
| Ucb, INC. | $155.60 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $134.00 | 2022-2025 | |
| Glaxosmithkline, LLC. | $93.16 | 2019-2025 | Benlysta |
| Radius Health, INC. | $90.65 | 2025 | Tymlos |
| Fresenius Kabi USA, LLC | $87.73 | 2023-2025 | Idacio |
| Genentech USA, INC. | $69.44 | 2022-2025 | Actemra, Rituxan |
| Kiniksa Pharmaceuticals International, Plc | $43.82 | 2024 | Arcalyst |
| Aurinia Pharma U.S., INC. | $36.54 | 2022-2023 | Lupkynis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $32.77 | 2023 | Krystexxa |
| Organon LLC | $29.35 | 2024 | |
| Sobi, INC | $27.55 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.79 | 2025 | Strensiq |
| Celgene Corporation | $23.84 | 2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.77 | 2023 | Cyltezo |
| Scilex Pharmaceuticals INC. | $18.21 | 2025 | |
| Sandoz INC. | $15.14 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.